An analogue peptide from the cancer testis antigen, PASD1, induces CD8+ T cell-responses against naturally processed peptide.

2.50
Hdl Handle:
http://hdl.handle.net/10547/578859
Title:
An analogue peptide from the cancer testis antigen, PASD1, induces CD8+ T cell-responses against naturally processed peptide.
Authors:
Hardwick, Nicola; Buchan, Sarah; Ingram, Wendy; Khan, Ghazala; Vittes, Gisella; Rice, Jason; Pulford, Karen; Mufti, Ghulam J.; Stevenson, Freda; Guinn, Barbara-Ann
Abstract:
We have previously identified the novel Cancer/Testis antigen PASD1 by immunoscreening a testis library with pooled acute myeloid leukemia (AML) patient sera. To develop a cytotoxic T lymphocyte (CTL)-inducing vaccine, we have now investigated the carboxy-terminal region, known to contain serological determinants, for MHC class I (HLA-A⋆0201)-binding peptides. Algorithm-selected natural peptides failed to show detectable HLA-A⋆0201 binding in T2 assays. However, anchor-modified analogue peptides showed enhanced binding, with decreased off-rates. Analogue peptide-loaded antigen-presenting cells (APCs) induced IFN-γ production by T cells from normal donors and patients. In addition, peptide-specific T cells could be expanded from cancer patients by stimulation with the PASD1 analogue peptide Pa14. For clinical application, a DNA fusion gene vaccine encoding Pa14 was designed and tested in "humanized" mice. Splenocytes from vaccinated mice showed in vitro cytotoxicity against tumour cells, either exogenously loaded with the corresponding wild-type peptide (Pw8) or expressing endogenously processed PASD1 protein. We show for the first time that a DNA vaccine encoding an altered PASD1 epitope can induce CTLs to target the natural peptide expressed by human tumour cells.
Affiliation:
King’s College London; University of Southampton; University of Bedfordshire; University of Oxford
Citation:
Hardwick, N.R., Buchan, S., Ingram, W., Khan, G., Vittes, G., Rice, J., Pulford, K., Mufti, G.J., Stevenson, F.K. & Guinn, B.A. (2013) 'An analogue peptide from the cancer testis antigen, PASD1, induces CD8+ T cell-responses against naturally processed peptide'. Cancer Immunity, 13, pp.16-26.
Publisher:
Cancer Research Institute
Issue Date:
2013
URI:
http://hdl.handle.net/10547/578859
PubMed Central ID:
PMC3718735
Additional Links:
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718735/; http://cancerimmunity.org/v13p16/
Type:
Article
Language:
en
ISSN:
1424-9634
Appears in Collections:
Biomedicine and Nutrition Research Group

Full metadata record

DC FieldValue Language
dc.contributor.authorHardwick, Nicolaen
dc.contributor.authorBuchan, Sarahen
dc.contributor.authorIngram, Wendyen
dc.contributor.authorKhan, Ghazalaen
dc.contributor.authorVittes, Gisellaen
dc.contributor.authorRice, Jasonen
dc.contributor.authorPulford, Karenen
dc.contributor.authorMufti, Ghulam J.en
dc.contributor.authorStevenson, Fredaen
dc.contributor.authorGuinn, Barbara-Annen
dc.date.accessioned2015-09-29T08:51:09Zen
dc.date.available2015-09-29T08:51:09Zen
dc.date.issued2013en
dc.identifier.citationHardwick, N.R., Buchan, S., Ingram, W., Khan, G., Vittes, G., Rice, J., Pulford, K., Mufti, G.J., Stevenson, F.K. & Guinn, B.A. (2013) 'An analogue peptide from the cancer testis antigen, PASD1, induces CD8+ T cell-responses against naturally processed peptide'. Cancer Immunity, 13, pp.16-26.en
dc.identifier.issn1424-9634en
dc.identifier.urihttp://hdl.handle.net/10547/578859en
dc.description.abstractWe have previously identified the novel Cancer/Testis antigen PASD1 by immunoscreening a testis library with pooled acute myeloid leukemia (AML) patient sera. To develop a cytotoxic T lymphocyte (CTL)-inducing vaccine, we have now investigated the carboxy-terminal region, known to contain serological determinants, for MHC class I (HLA-A⋆0201)-binding peptides. Algorithm-selected natural peptides failed to show detectable HLA-A⋆0201 binding in T2 assays. However, anchor-modified analogue peptides showed enhanced binding, with decreased off-rates. Analogue peptide-loaded antigen-presenting cells (APCs) induced IFN-γ production by T cells from normal donors and patients. In addition, peptide-specific T cells could be expanded from cancer patients by stimulation with the PASD1 analogue peptide Pa14. For clinical application, a DNA fusion gene vaccine encoding Pa14 was designed and tested in "humanized" mice. Splenocytes from vaccinated mice showed in vitro cytotoxicity against tumour cells, either exogenously loaded with the corresponding wild-type peptide (Pw8) or expressing endogenously processed PASD1 protein. We show for the first time that a DNA vaccine encoding an altered PASD1 epitope can induce CTLs to target the natural peptide expressed by human tumour cells.en
dc.language.isoenen
dc.publisherCancer Research Instituteen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3718735/en
dc.relation.urlhttp://cancerimmunity.org/v13p16/en
dc.subjectDNA vaccineen
dc.subjectPASD1en
dc.subjectacute myeloid leukemiaen
dc.subjectanalogue peptideen
dc.subjectimmunotherapyen
dc.titleAn analogue peptide from the cancer testis antigen, PASD1, induces CD8+ T cell-responses against naturally processed peptide.en
dc.typeArticleen
dc.contributor.departmentKing’s College Londonen
dc.contributor.departmentUniversity of Southamptonen
dc.contributor.departmentUniversity of Bedfordshireen
dc.contributor.departmentUniversity of Oxforden
dc.identifier.pmcidPMC3718735en
All Items in UOBREP are protected by copyright, with all rights reserved, unless otherwise indicated.